These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24365381)

  • 21. Inflammatory pathways in patients with heart failure and preserved ejection fraction.
    Niethammer M; Sieber M; von Haehling S; Anker SD; Munzel T; Horstick G; Genth-Zotz S
    Int J Cardiol; 2008 Sep; 129(1):111-7. PubMed ID: 17658631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How often we need to measure brain natriuretic peptide (BNP) blood levels in patients admitted to the hospital for acute severe heart failure? Role of serial measurements to improve short-term prognostic stratification.
    Faggiano P; Valle R; Aspromonte N; D'Aloia A; Di Tano G; Barro S; Giovinazzo P; Milani L; Lorusso R; Dei Cas L
    Int J Cardiol; 2010 Apr; 140(1):88-94. PubMed ID: 19321212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The involvement of galectin-3 in heart failure].
    Kałan M; Witczak A; Mosiewicz J; Donica H
    Postepy Hig Med Dosw (Online); 2015 Sep; 69():1107-13. PubMed ID: 26400896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlations between clinical presentation, brain natriuretic peptide, big endothelin-1, tumor necrosis factor-alpha and cardiac troponins in heart failure patients.
    Boffa GM; Zaninotto M; Bacchiega E; Nalli C; Forni M; Tiso E; Cacciavillani L; Razzolini R; Plebani M
    Ital Heart J; 2005 Feb; 6(2):125-32. PubMed ID: 15819505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The clinical value of B-type natriuretic peptide in the diagnosis of left heart failure].
    Zhao XY; Yang YJ; Zhang J; Dang AM; Ni XH; Huang J; Kang S; Ma WH; Zhao DY
    Zhonghua Yi Xue Za Zhi; 2006 May; 86(17):1165-9. PubMed ID: 16796855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
    Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.
    Ho JE; Liu C; Lyass A; Courchesne P; Pencina MJ; Vasan RS; Larson MG; Levy D
    J Am Coll Cardiol; 2012 Oct; 60(14):1249-56. PubMed ID: 22939561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Natriuretic peptides--new diagnostic markers in heart disease].
    Angermann CE; Ertl G
    Herz; 2004 Sep; 29(6):609-17. PubMed ID: 15912436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure.
    McCullough PA; Olobatoke A; Vanhecke TE
    Rev Cardiovasc Med; 2011; 12(4):200-10. PubMed ID: 22249510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation.
    Beiras-Fernandez A; Weis F; Rothkopf J; Kaczmarek I; Ledderose C; Dick A; Keller T; Beiras A; Kreth S
    Ann Transplant; 2013 Nov; 18():643-50. PubMed ID: 24264380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.
    Lin YH; Lin LY; Wu YW; Chien KL; Lee CM; Hsu RB; Chao CL; Wang SS; Hsein YC; Liao LC; Ho YL; Chen MF
    Clin Chim Acta; 2009 Nov; 409(1-2):96-9. PubMed ID: 19747906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
    Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
    Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure.
    Meijers WC; van der Velde AR; de Boer RA
    Expert Rev Mol Diagn; 2014 Apr; 14(3):257-66. PubMed ID: 24606321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The predictive value of plasma biomarkers in discharged heart failure patients: role of galectin-3.
    Leone M; Iacoviello M
    Minerva Cardioangiol; 2016 Apr; 64(2):181-94. PubMed ID: 26426300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Galectin-3 and Arterial Stiffness in Patients with Heart Failure: A Pilot Study.
    Oikonomou E; Karlis D; Tsalamadris S; Siasos G; Chrysohoou C; Vogiatzi G; Dimitropoulos S; Charalambous G; Kouskouni E; Tousoulis D
    Curr Vasc Pharmacol; 2019; 17(4):396-400. PubMed ID: 29968538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multi-center validation of the Response Biomedical Corporation RAMP NT-proBNP assay with comparison to the Roche Diagnostics GmbH Elecsys proBNP assay.
    Lee-Lewandrowski E; Januzzi JL; Green SM; Tannous B; Wu AH; Smith A; Wong A; Murakami MM; Kaczmarek J; Apple FS; Miller WL; Hartman K; Jaffe AS
    Clin Chim Acta; 2007; 386(1-2):20-4. PubMed ID: 17854790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study.
    Voors AA; von Haehling S; Anker SD; Hillege HL; Struck J; Hartmann O; Bergmann A; Squire I; van Veldhuisen DJ; Dickstein K;
    Eur Heart J; 2009 May; 30(10):1187-94. PubMed ID: 19346228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices.
    Erkilet G; Özpeker C; Böthig D; Kramer F; Röfe D; Bohms B; Morshuis M; Gummert J; Milting H
    J Heart Lung Transplant; 2013 Feb; 32(2):221-30. PubMed ID: 23352394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
    Anand IS; Rector TS; Kuskowski M; Adourian A; Muntendam P; Cohn JN
    Eur J Heart Fail; 2013 May; 15(5):511-8. PubMed ID: 23291728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.